Browse by Person

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 5.

Article

Kater, AP, Seymour, JF, Hillmen, P orcid.org/0000-0001-5617-4403 et al. (12 more authors) (2019) Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. Journal of Clinical Oncology, 34 (4). pp. 269-277. ISSN 0732-183X

Robak, T, Burger, JA, Tedeschi, A et al. (23 more authors) (2018) Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies. American Journal of Hematology, 93 (11). pp. 1402-1410. ISSN 0361-8609

Seymour, JF, Kipps, TJ, Eichhorst, B et al. (17 more authors) (2018) Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England Journal of Medicine, 378 (12). pp. 1107-1120. ISSN 0028-4793

Burger, JA, Tedeschi, A, Barr, PM et al. (31 more authors) (2015) Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. New England Journal of Medicine, 373 (25). pp. 2425-2437. ISSN 0028-4793

Proceedings Paper

Burger, J, Tedeschi, A, Barr, PM et al. (32 more authors) (2016) International, randomized phase 3 study results: Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM)). In: Oncology Research and Treatment. Annual conference of the German, Austrian and Swiss Societies for Haematology and Medical Oncology, 14-18 Oct 2016, Leipzig, Germany. Karger Publishers , p. 6.

This list was generated on Sun Jul 14 22:50:50 2019 BST.